Gilead Sciences, Inc. (Nasdaq: GILD) will present new findings from its antiviral research and development programs at IDWeek ...

AstraZeneca and Gilead both reported successful trials in a hard-to-treat form of breast cancer, sparking a debate about ...

In the first opportunity for industry watchers to compare the two approved TROP2 antibody-drug conjugates side by side in ...

Gilead Sciences' Trodelvy lowered the risk of disease progression in an aggressive type of breast cancer by 38% when used as ...

Discover why Gilead Sciences (GILD) is a top healthcare stock in 2025 with strong fundamentals and growth potential.

BERLIN -- For the first time in a phase III trial, adjuvant treatment with a CDK4/6 inhibitor significantly improved overall ...

Patients with previously untreated, locally advanced, unresectable or metastatic triple-negative breast cancer who are not ...

Shares of Gilead Sciences Inc. rose 4.21% to $122.81 Friday, on what proved to be an all-around great trading session for the ...

Source: ‘Miracle’ HIV shot rollout in Zimbabwe sparks debate – DW – 10/16/2025 Zimbabwe is among 10 nations rolling out ...

Kite has paid $120 million upfront to Pregene to gain certain license rights and to collaborate on developing in vivo cell therapies with the Shenzhen, China-based firm. Pregene is entitled to receive ...

T, this time inking a deal worth up to $1.64 billion biobucks with Chinese biotech Pregene Biopharma. | Gilead’s Kite Pharma is doubling down on in vivo CAR-T, this time inking a deal worth up to ...